Edwards Lifesciences (XSWX:EW) Piotroski F-Score: 5 (As of Jun. 26, 2026) — 17% Below Median


XSWX:EW Edwards Lifesciences Corp XSWX:EW
97 GF Score
Price CHF72.91
GF Value CHF75.73
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Piotroski F-Score?

Edwards Lifesciences XSWX:EW +0.37% 97 Piotroski F-Score is 5 as of Jun. 26, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates XSWX:EW with a GF Score™ of 97/100 and a GF Value™ of CHF75.73. The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 64.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Edwards Lifesciences's Piotroski F-Score or its related term are showing as below:

XSWX:EW' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Edwards Lifesciences was 8. The lowest was 5. And the median was 6.

Edwards Lifesciences  (XSWX:EW) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Edwards Lifesciences Piotroski F-Score Related Terms


Edwards Lifesciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Piotroski F-Score Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 5.00 6.00 7.00 5.00

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 5.00 5.00 5.00

XSWX:EW vs DXCM, GEHC, BSX: Piotroski F-Score Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Piotroski F-Score falls into.


XSWX:EW
97GF Score
Edwards Lifesciences Corp XSWX:EW
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 268.193 + 231.745 + 72.677 + 299.725 = CHF872 Mil.
Cash Flow from Operations was 235.991 + 456.723 + 359.322 + 34.484 = CHF1,087 Mil.
Revenue was 1245.985 + 1236.423 + 1250.814 + 1297.943 = CHF5,031 Mil.
Gross Profit was 965.919 + 961.609 + 977.478 + 1012.468 = CHF3,917 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(11506.504 + 10969.011 + 10565.998 + 10915.299 + 10487.781) / 5 = CHF10888.9186 Mil.
Total Assets at the begining of this year (Mar25) was CHF11,507 Mil.
Long-Term Debt & Capital Lease Obligation was CHF534 Mil.
Total Current Assets was CHF4,904 Mil.
Total Current Liabilities was CHF1,109 Mil.
Net Income was 325.075 + 2601.582 + 343.801 + 316.329 = CHF3,587 Mil.

Revenue was 1223.97 + 1147.448 + 1235.579 + 1248.262 = CHF4,855 Mil.
Gross Profit was 977.728 + 924.719 + 975.054 + 981.768 = CHF3,859 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(8651.676 + 9026.754 + 10989.201 + 11640.105 + 11506.504) / 5 = CHF10362.848 Mil.
Total Assets at the begining of last year (Mar24) was CHF8,652 Mil.
Long-Term Debt & Capital Lease Obligation was CHF597 Mil.
Total Current Assets was CHF5,490 Mil.
Total Current Liabilities was CHF1,232 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Net Income (TTM) was 872. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Cash Flow from Operations (TTM) was 1,087. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=872.34/11506.504
=0.07581278

ROA (Last Year)=Net Income/Total Assets (Mar24)
=3586.787/8651.676
=0.41457713

Edwards Lifesciences's return on assets of this year was 0.07581278. Edwards Lifesciences's return on assets of last year was 0.41457713. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Edwards Lifesciences's current Net Income (TTM) was 872. Edwards Lifesciences's current Cash Flow from Operations (TTM) was 1,087. ==> 1,087 > 872 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=534.262/10888.9186
=0.04906474

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=597.049/10362.848
=0.05761437

Edwards Lifesciences's gearing of this year was 0.04906474. Edwards Lifesciences's gearing of last year was 0.05761437. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4903.856/1109.306
=4.42065219

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=5489.542/1232.445
=4.45418822

Edwards Lifesciences's current ratio of this year was 4.42065219. Edwards Lifesciences's current ratio of last year was 4.45418822. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Edwards Lifesciences's number of shares in issue this year was 580.7. Edwards Lifesciences's number of shares in issue last year was 587.8. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3917.474/5031.165
=0.77864153

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3859.269/4855.259
=0.79486367

Edwards Lifesciences's gross margin of this year was 0.77864153. Edwards Lifesciences's gross margin of last year was 0.79486367. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5031.165/11506.504
=0.43724532

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4855.259/8651.676
=0.56119288

Edwards Lifesciences's asset turnover of this year was 0.43724532. Edwards Lifesciences's asset turnover of last year was 0.56119288. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Edwards Lifesciences (XSWX:EW) has a Piotroski F-Score of 5 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Edwards Lifesciences and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Edwards Lifesciences' Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, Edwards Lifesciences ranks #282 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is Edwards Lifesciences' Piotroski F-Score too high?
Edwards Lifesciences' current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Edwards Lifesciences' value of 5 is 0% at this industry median. Based on the distribution chart, Edwards Lifesciences ranks #282 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Piotroski F-Score compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #282 out of 805 companies for Piotroski F-Score. This puts Edwards Lifesciences in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Edwards Lifesciences' value of 5 is 0% at this benchmark. Historically, Edwards Lifesciences' own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Edwards Lifesciences has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Piotroski F-Score of 5. The stock's GF Value™ is CHF75.73, compared to a current price of CHF72.91 — trading 3.7% below its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Medical Devices & Instruments industry median of 5.00. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Piotroski F-Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF72.91 is trading 3.7% below its estimated GF Value™ of CHF75.73.

Key valuation signals for XSWX:EW:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: CHF75.73 vs. price of CHF72.91 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#282 of 805)

No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for XSWX:EW

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.91
Price
CHF75.73
GF Value